Amfetamin Tipi Stimülanlar

Authors

Rukiye Aslan
https://orcid.org/0000-0002-4012-3684
Mine Kadıoğlu Duman

Synopsis

This book chapter examines the chemical structures, history, clinical and legal status, pharmacokinetic properties, analytical methods, and forensic dimensions of amphetamine-type stimulants (ATS). ATS encompasses synthetic central nervous system stimulants such as amphetamine, methamphetamine, MDMA, and methylphenidate. First synthesized in the late 19th century, these substances have been utilized in the treatment of asthma, obesity, and ADHD, while also being widely abused for their alertness- and energy-enhancing effects. They exert their action by promoting the release of dopamine, norepinephrine, and serotonin from presynaptic nerve terminals. In the body, they can cause addiction, euphoria, cardiovascular damage, psychosis, and fatal toxic effects. Biological specimens such as urine, blood, oral fluid, hair, and sweat are employed for the forensic toxicological analysis of ATS and their metabolites. Screening tests performed via immunoassay techniques carry a risk of false positives caused by cross-reacting substances like pseudoephedrine, necessitating confirmation through GC-MS and LC-MS/MS methods. Representing the most commonly abused illicit drug group after cannabis, the use of ATS is prohibited under the Turkish Penal Code (TCK Article 191) and international conventions. Since no specific pharmacological therapy with consistent efficacy exists for ATS addiction, psychosocial interventions remain the primary treatment approach.

References

Heal DJ, Smith SL, Gosden J, et al. Amphetamine, past and present - A pharmacological and clinical perspective. Journal of Psychopharmacology. SAGE Publications; 2013;27(6): 479–496. doi:10.1177/0269881113482532

Greene SL, Kerr F, Braitberg G. Review article: Amphetamines and related drugs of abuse. EMA - Emergency Medicine Australasia. Emerg Med Australas; 2008;20(5): 391–402. doi:10.1111/j.1742-6723.2008.01114.x

Simola N, Carta M. Amphetamine Usage, Misuse, and Addiction Processes: An Overview. Neuropathology of Drug Addictions and Substance Misuse. Elsevier Inc.; 2016. p. 14–24. doi:10.1016/B978-0-12-800212-4.00002-9

Vearrier D, Greenberg MI, Miller SN, et al. Methamphetamine: History, Pathophysiology, Adverse Health Effects, Current Trends, and Hazards Associated with the Clandestine Manufacture of Methamphetamine. Disease-a-Month. Dis Mon; 2012;58(2): 38–89. doi:10.1016/j.disamonth.2011.09.004

Topp L, Degenhardt L, Kaye S, et al. The emergence of potent forms of methamphetamine in Sydney, Australia: A case study of the IDRS as a strategic early warning system. Drug and Alcohol Review. Drug Alcohol Rev; 2002;21(4): 341–348. doi:10.1080/0959523021000023199

Australian Governtment Department of Health and Ageing. National Drug Strategy. National Amphetamine-Type Stimulant Strategy Background Paper. 2011.

Levine B. Principles of Forensic Toxicology.. 4th ed. Levine B (ed.) AACC Press; 2013. 265–285 p.

Pentney AR. An exploration of the history and controversies surrounding MDMA and MDA. Journal of Psychoactive Drugs. J Psychoactive Drugs; 2001;33(3): 213–221. doi:10.1080/02791072.2001.10400568

Reddy DS. Current pharmacotherapy of attention deficit hyperactivity disorder. Drugs of Today. Drugs Today (Barc); 2013;49(10): 647–665. doi:10.1358/dot.2013.49.10.2008996

Ricca V, Castellini G, Mannucci E, et al. Amphetamine derivatives and obesity. Appetite. Academic Press; 2009;52(2): 405–409. doi:10.1016/j.appet.2008.11.013

Cosentino G, Conrad AO, Uwaifo GI. Phentermine and topiramate for the management of obesity: A review. Drug Design, Development and Therapy. Dove Press; 2013;7: 267–278. doi:10.2147/DDDT.S31443

Lexicomp Drug Information. Amphetamine sulfate. [Online] https://www.uptodate.com/contents/amphetamine-sulfate-drug-%0Ainformation?search=Amphetaminepharmakokinetics&source=panel_search_result&selected%0ATitle=1~117&usage_type=panel&kp_tab=drug_general&display_rank=1#F238381.

Martin Paulus. Methamphetamine use disorder: Epidemiology, clinical manifestations, course, assessment, and diagnosis. [Online] Uptodate. https://www.uptodate.com/contents/methamphetamine-use-disorder-epidemiology-clinical-manifestations-course-assessment-and-diagnosis

Kayaalp S, Uzbay T. İlaç kötüye kullanımı ve ilaç bağımlılığı. In: Kayaalp S (ed.) Akılcıl Tedavi Yönünden Tıbbi Farmakoloji. Pelikan Yayınları; 2015. p. 868.

Kadıoğlu Duman M. İlaç Suistimali. In: Şener G, Gören Z, Okuyan B, Yeğen B (eds.) Güncel Farmakoloji: Fizyoloji Temelinde Hasta Odaklı Yaklaşım. Ankara: Güneş Tıp Kitabevi; 2021.

Robert J Hoffman. MDMA (ecstasy) intoxication. [Online] UpToDate. https://www.uptodate.com/contents/mdma-ecstasy-intoxication?search=ectasy&source=search_result&selectedTitle=1~125&usage_type=default&display_rank=1

Kaygısız B. Medikal tedavi ile bağımlılık. In: Kılıç F (ed.) Bağımlılık Yapan İlaçlara ve Maddelere Genel Bakış ve Farkındalık. 1st ed. Ankara: Türkiye Klinikleri; 2020. p. 42–46.

Saito K, Saito R, Kikuchi Y, et al. Analysis of Drugs of Abuse in Biological Specimens. JOURNAL OF HEALTH SCIENCE. Pharmaceutical Society of Japan; 2011;57(6): 472–487. doi:10.1248/jhs.57.472

Mali N, Karpe M, Kadam V. A review on biological matrices and analytical methods used for determination of drug of abuse.

Villain M, Cirimele V, Kintz P. Hair analysis in toxicology. Clinical Chemistry and Laboratory Medicine. Clin Chem Lab Med; 2004;42(11): 1265–1272. doi:10.1515/CCLM.2004.247

Jadoon S, Karim S, Asad MHH Bin, et al. Anti-aging potential of phytoextract loaded-pharmaceutical creams for human skin cell longetivity. Oxidative Medicine and Cellular Longevity. Hindawi Publishing Corporation; 2015;2015. doi:10.1155/2015/709628

Verstraete AG. Detection Times of Drugs of Abuse in Blood, Urine, and Oral Fluid. Therapeutic Drug Monitoring. Ther Drug Monit; 2004;26(2): 200–205. doi:10.1097/00007691-200404000-00020

Cone EJ. Recent discoveries in pharmacokinetics of drugs of abuse. Toxicology Letters. Toxicol Lett; 1998;102–103: 97–101. doi:10.1016/S0378-4274(98)00292-6

Schep LJ, Slaughter RJ, Beasley DMG. The clinical toxicology of metamfetamine. Clinical Toxicology. Informa Healthcare; 2010;48(7): 675–694. doi:10.3109/15563650.2010.516752

Vandevenne M, Vandenbussche H, Verstraete A. Detection time of drugs of abuse in urine. Acta Clinica Belgica. Acta Clinica Belgica; 2000;55(6): 323–333. doi:10.1080/17843286.2000.11754319

Wan SH, Matin SB, Azarnoff DL. Kinetics, salivary excretion of amphetamine isomers, and effect of urinary pH. Clinical Pharmacology and Therapeutics. Clin Pharmacol Ther; 1978;23(5): 585–590. doi:10.1002/cpt1978235585

Perrigo BJ, Joynt BP. Use of Elisa for the Detection of Common Drugs of Abuse in Forensic Whole Blood Samples. Can. Soc. Forensic Sci. J. Taylor & Francis; 2013;28(4): 261–269. doi:10.1080/00085030.1995.10757486

Quintela O, López P, Bermejo A, et al. Determination of methadone, 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine and alprazolam in human plasma by liquid chromatography-electrospray ionization mass spectrometry. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. J Chromatogr B Analyt Technol Biomed Life Sci; 2006;834(1–2): 188–194. doi:10.1016/J.JCHROMB.2006.02.013

Loor R, Lingenfelter C, Wason PP, et al. Multiplex assay of amphetamine, methamphetamine, and ecstasy drug using CEDIA® technology. Journal of Analytical Toxicology. Preston Publications; 2002;26(5): 267–273. doi:10.1093/jat/26.5.267

Stout PR, Klette KL, Horn CK. Evaluation of Ephedrine, Pseudoephedrine and Phenylpropanolamine Concentrations in Human Urine Samples and a Comparison of the Specificity of DRI® Amphetamines and Abuscreen® Online (KIMS) Amphetamines Screening Immunoassays. Journal of Forensic Sciences. ASTM International; 2004;49(1): 1–5. doi:10.1520/jfs2003233

K D Eskridge, S K Guthrie. Clinical issues associated with urine testing of substances of abuse. Pharmacotherapy. 1997;17(3): 497–510.

Hsu J, Liu C, Hsu CP, et al. Performance characteristics of selected immunoassays for preliminary test of 3,4-methylenedioxymethamphetamine, methamphetamine, and related drugs in urine specimens. Journal of Analytical Toxicology. Preston Publications; 2003;27(7): 471–478. doi:10.1093/jat/27.7.471

Cody JT. Precursor medications as a source of methamphetamine and/or amphetamine positive drug testing results. Journal of Occupational and Environmental Medicine. Lippincott Williams and Wilkins; 2002;44(5): 435–450. doi:10.1097/00043764-200205000-00012

Moeller KE, Lee KC, Kissack JC. Urine drug screening: Practical guide for clinicians. Mayo Clinic Proceedings. Elsevier Ltd; 2008;83(1): 66–76. doi:10.4065/83.1.66

Substance Abuse and Mental Health Services Administration. Federal Workplace Drug Testing Program; Proposed Mandatory Guidelines: Hair, sweat, oral fluid, and urine specimens testing; scientific and technical guidelines. 2004.

Moore KA. Amphetamines/sympathomimetic amines. In: Levine B (ed.) Principles of Forensic Toxicology. Washington D.C; 2003. p. 341–348.

Kraemer T, Maurer HH. Determination of amphetamine, methamphetamine and amphetamine-derived designer drugs or medicaments in blood and urine. Journal of Chromatography B: Biomedical Applications. Elsevier; 1998;713(1): 163–187. doi:10.1016/S0378-4347(97)00515-X

Mercieca G, Odoardi S, Cassar M, et al. Rapid and simple procedure for the determination of cathinones, amphetamine-like stimulants and other new psychoactive substances in blood and urine by GC–MS. Journal of Pharmaceutical and Biomedical Analysis. Elsevier B.V.; 2018;149: 494–501. doi:10.1016/j.jpba.2017.11.024

Baciu T, Borrull F, Aguilar C, et al. Recent trends in analytical methods and separation techniques for drugs of abuse in hair. Analytica Chimica Acta. Elsevier; 2015;856: 1–26. doi:10.1016/j.aca.2014.06.051

Chen X, Wu X, Luan T, et al. Sample preparation and instrumental methods for illicit drugs in environmental and biological samples: A review. Journal of Chromatography A. Elsevier B.V.; 2021;1640: 461961. doi:10.1016/j.chroma.2021.461961

Shin Y, Kong TY, Cheong JC, et al. Simultaneous determination of 75 abuse drugs including amphetamines, benzodiazepines, cocaine, opioids, piperazines, zolpidem and metabolites in human hair samples using liquid chromatography–tandem mass spectrometry. Biomedical Chromatography. John Wiley and Sons Ltd; 2019;33(9). doi:10.1002/bmc.4600

Vincenti F, Montesano C, Cellucci L, et al. Combination of pressurized liquid extraction with dispersive liquid liquid micro extraction for the determination of sixty drugs of abuse in hair. Journal of Chromatography A. Elsevier B.V.; 2019;1605. doi:10.1016/j.chroma.2019.07.002

Fernández P, González M, Regenjo M, et al. Analysis of drugs of abuse in human plasma using microextraction by packed sorbents and ultra-high-performance liquid chromatography. Journal of Chromatography A. Elsevier B.V.; 2017;1485: 8–19. doi:10.1016/j.chroma.2017.01.021

Baciu T, Borrull F, Aguilar C, et al. Findings in the hair of drug abusers using pressurized liquid extraction and solid-phase extraction coupled in-line with capillary electrophoresis. Journal of Pharmaceutical and Biomedical Analysis. Elsevier B.V.; 2016;131: 420–428. doi:10.1016/j.jpba.2016.09.017

Mamat NA, See HH. Development and evaluation of electromembrane extraction across a hollow polymer inclusion membrane. Journal of Chromatography A. Elsevier; 2015;1406: 34–39. doi:10.1016/j.chroma.2015.06.020

Rezazadeh M, Yamini Y, Seidi S. Application of a new nanocarbonaceous sorbent in electromembrane surrounded solid phase microextraction for analysis of amphetamine and methamphetamine in human urine and whole blood. Journal of Chromatography A. Elsevier; 2015;1396: 1–6. doi:10.1016/j.chroma.2015.03.077

Yang Y, Wu J, Deng J, et al. Rapid and on-site analysis of amphetamine-type illicit drugs in whole blood and raw urine by slug-flow microextraction coupled with paper spray mass spectrometry. Analytica Chimica Acta. Elsevier B.V.; 2018;1032: 75–82. doi:10.1016/j.aca.2018.06.006

Argente-García AI, Moliner-Martínez Y, López-García E, et al. Application of carbon nanotubes modified coatings for the determination of amphetamines by in-tube solid-phase microextraction and capillary liquid chromatography. Separations. MDPI Multidisciplinary Digital Publishing Institute; 2016;3(1). doi:10.3390/chromatography3010007

Song A, Yang J. Efficient determination of amphetamine and methylamphetamine in human urine using electro-enhanced single-drop microextraction with in-drop derivatization and gas chromatography. Analytica Chimica Acta. Elsevier B.V.; 2019;1045: 162–168. doi:10.1016/j.aca.2018.09.024

EMCDDA. Avrupa Uyuşturucu Raporu Eğilimler ve Gelişmeler. [Online] 2018. doi:10.2810/113105

European Monitoring Center for Drugs and Drug Addiction (EMCDDA). Statistical Bulletin 2020. [Online] https://www.emcdda.europa.eu/data/stats2020_en

European Monitoring Center for Drugs and Drug Addiction (EMCDDA). Turkey Country Drug Report 2019. [Online] 2019. https://www.emcdda.europa.eu/publications/country-drug-reports/2019/turkey_en

Carvalho M, Carmo H, Costa VM, et al. Toxicity of amphetamines: An update. Archives of Toxicology. Arch Toxicol; 2012;86(8): 1167–1231. doi:10.1007/s00204-012-0815-5

Kaplan Y, Demir Ö. Amfetamin ve Benzeri Maddeler. In: Akgür S, Coşkunol H (eds.) Bağımlılık Yapan Maddeler ve Toksikolojisi. İzmir: Ege Üniversitesi Basımevi; 2014. p. 105–116.

Uyuşturucu Maddelere Dair TEK Sözleşmesi. [Online] 1961. https://www.tbmm.gov.tr/tutanaklar/KANUNLAR_KARARLAR/kanuntbmmc050/kanuntbmmc050/kanuntbmmc05000812.pdf

Albrecht MA, Roberts G, Price G, et al. The effects of dexamphetamine on the resting-state electroencephalogram and functional connectivity. Human Brain Mapping. John Wiley and Sons Inc.; 2016;37(2): 570–588. doi:10.1002/hbm.23052

Docherty J. Pharmacology of stimulants prohibited by the World Anti-Doping Agency (WADA). British journal of pharmacology. Br J Pharmacol; 2008;154(3): 606–622. doi:10.1038/BJP.2008.124

Girotto E, Mesas AE, De Andrade SM, et al. Psychoactive substance use by truck drivers: A systematic review. Occupational and Environmental Medicine. Occup Environ Med; 2014;71(1): 71–76. doi:10.1136/oemed-2013-101452

Gustavsen I, Mørland J, Bramness JG. Impairment related to blood amphetamine and/or methamphetamine concentrations in suspected drugged drivers. Accident Analysis & Prevention. 2006;38(3): 490–495. doi:10.1016/j.aap.2005.11.005

Aktaş A, Döğer R, Akgür SA. The Evaluation of Driver Behaviors and Skills Relation with Consumption of Alcohol, Drug Abuse and Medicine in Professional Drivers. The Bulletin of Legal Medicine. 2019;24(2): 100–107.

McCabe SE, West BT, Teter CJ, et al. Trends in medical use, diversion, and nonmedical use of prescription medications among college students from 2003 to 2013: Connecting the dots. Addictive Behaviors. Elsevier Ltd; 2014;39(7): 1176–1182. doi:10.1016/j.addbeh.2014.03.008

Kyle Kampman. Pharmacotherapy for stimulant use disorders in adults. [Online] Uptodate. https://www.uptodate.com/contents/pharmacotherapy-for-stimulant-use-disorders-in-adults?search=cocaineusedisorder&source=search_result&selectedTitle=3~150&usage_type=default&display_rank=3

Kulaksızoğlu B, Kulaksızoğlu S, Ellidağ H, et al. Antalya ilinde denetimli serbestlik karan alınan kişilerde uyuşturucu madde kullanımının araştınlması. Adli Tıp Bülteni. 2015;20(1): 21–26.

Published

November 4, 2021

License

License